Tag
Acmopatide, a novel biased GLP-1/GIP receptor agonist, improves glycemic control and reduces body weight without severe adverse events in overweight adults with type 1 diabetes, based on a 16-week phase 2 randomized trial.
Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, significantly reduces bodyweight and improves glycemic control in adults with obesity and type 2 diabetes, showing promising efficacy and a manageable safety profil
In the SELECT trial, baseline clinical factors poorly predicted peak body weight loss with semaglutide, highlighting the role of sex and dosage but underscoring substantial unexplained variability in patient response.
A 12-week randomized trial compared the effects of calorie-restricted DASH, carbohydrate-restricted, and low-purine diets on weight loss and serum urate levels in men with overweight or obesity and hyperuricemia, highlighting adherence and
This study investigates postoperative complication rates following body-contouring surgery among patients with differing weight-loss methods, revealing that weight-loss modality does not affect complications, while BMI and diabetes at surge
This study evaluates complication rates following body contouring after weight loss via bariatric surgery, GLP-1 receptor agonists, combination therapy, and lifestyle changes, finding weight-loss modality does not affect postoperative compl
Early weight loss after impaired glucose tolerance diagnosis is linked to markedly reduced long-term risk of cardiovascular events and death, underscoring the importance of early lifestyle interventions in prediabetes management.
Mazdutide, a once-weekly glucagon and GLP-1 receptor dual agonist, delivers clinically meaningful weight reduction in adults with obesity or overweight, with higher doses yielding superior outcomes and manageable safety profiles.
A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with
In a large U.K. cohort, losing at least 15% of body weight within 2 years of type 2 diabetes diagnosis was linked to lower risks of heart, kidney, and eye complications, along with better glucose and blood pressure control.
In adults with early type 2 diabetes inadequately controlled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, body weight, and waist circumference than intensified conventional care, with substantially higher rates of
In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antip
The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while em
A dual-tracer study reveals that behavioral diet therapy provides greater postprandial glycemic improvement than Roux-en-Y gastric bypass after 20% weight loss in people with type 2 diabetes, driven by enhanced insulin-mediated glucose disp
This review synthesizes evidence on tailored weight loss programs for adults with serious mental illness, highlighting recent advances, effectiveness, mechanistic insights, and future directions.
This review synthesizes evidence from a 2025 randomized clinical trial evaluating a tailored weight loss program, CoachToFit, for veterans with serious mental illness, highlighting its potential to improve weight outcomes via remote support
In patients with overweight/obesity and cardiometabolic comorbidity undergoing first-time AF ablation, a structured, physician‑led program of lifestyle and risk‑factor modification (LRFM) improved freedom from atrial arrhythmia at 12 months
A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promisi
In a 48‑week multicenter phase 2 trial, weekly amylin receptor agonist eloralintide produced dose‑dependent mean weight loss of 9.4%–20.9% versus 0.4% for placebo, with improved waist circumference and cardiometabolic markers; tolerability
This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits
